

3rd March 2021

**THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.**

**Phimedix Plc**

("Phimedix" or "the Company")

**AIM Rule 15 Update**

Further to its announcement on 18 January 2021, Phimedix (AIM: PHM), the AIM Rule 15 cash shell, announces that the proposed acquisition in the life sciences space will not now be proceeding.

As no reverse takeover will be completed by 14 March 2021, being the date six months following the suspension of trading in the Company's shares, the London Stock Exchange will cancel the admission of Phimedix's ordinary shares to trading on AIM ("Cancellation") with effect from 7.30 a.m. on Monday 15 March 2021.

After Cancellation, the Company will explore its available options, and keep shareholders informed as and when appropriate.

**Phimedix Plc**

Nicholas Nelson, Director

Ajay Rajpal, Director

**Please email any enquiries  
to [nelson@nexfin.org.uk](mailto:nelson@nexfin.org.uk)**

**SPARK Advisory Partners Limited (Nominated Adviser)**

**0203 368 3550**

Mark Brady or James Keeshan

[www.sparkadvisorypartners.com](http://www.sparkadvisorypartners.com)

**SI Capital Limited (Broker)**

**01483 413500**

Nick Emerson

[www.sicapital.co.uk](http://www.sicapital.co.uk)